Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.
Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Hôpital de la Conception, Marseille, France.
Kidney Int. 2021 May;99(5):1062-1064. doi: 10.1016/j.kint.2021.01.008.
Sodium-glucose cotransporter 2 inhibitors offer cardiovascular and renal benefits in patients with chronic kidney disease through not yet clearly defined mechanisms. Juni et al. showed that sodium-glucose cotransporter 2 inhibitor empagliflozin exposure in vitro can restore cardiomyocyte function by counteracting harmful effects of uremic serum on the endothelium-cardiomyocyte crosstalk between endothelial cells and cardiomyocytes. The author's findings improved our understanding of cardiovascular impairment in chronic kidney disease and provided new perspectives for the beneficial effects of sodium-glucose cotransporter 2 inhibitor therapy.
钠-葡萄糖共转运蛋白 2 抑制剂通过尚未明确的机制为慢性肾脏病患者带来心血管和肾脏获益。Juni 等人表明，钠-葡萄糖共转运蛋白 2 抑制剂恩格列净在体外的暴露可以通过抵消尿毒症血清对内皮细胞-心肌细胞之间的内皮细胞-心肌细胞串扰的有害影响来恢复心肌细胞功能。作者的发现增进了我们对慢性肾脏病中心血管损伤的理解，并为钠-葡萄糖共转运蛋白 2 抑制剂治疗的有益作用提供了新的视角。
